HK's Biostime to buy Australian vitamin maker Swisse for over US$1b: media
[SYDNEY] Hong Kong-listed dietary supplements company Biostime International Holdings has agreed to buy Australian vitamin maker Swisse Wellness for more than A$1.5 billion (S$1.5 billion), Australian media reported on Thursday.
The company beat Shanghai Pharmaceuticals Holding and Chinese private equity firm Hony Capital in a sale managed by Goldman Sachs Group Inc, the Australian newspaper and Fairfax Media said in reports, citing unnamed sources.
Swisse and Goldman Sachs were not immediately available for comment. Biostime issued a statement saying it had requested a trading halt for its shares, without giving an explanation.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Swiss watch exports plunge as China and Hong Kong demand dries up
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Billionaires selling cheap stuff get richer from inflation pain
Amazon to push cashierless shopping tech into more third-party stores, while backing off itself
Japan’s Uniqlo opens Rome store as part of European expansion
Abbott beats quarterly profit estimates on strong medical device sales